Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mitemcinal

Next Previous
X
Search
Drug Profile

Mitemcinal

Alternative Names: GM-611; Mitemcinal-Fumarate

Latest Information Update: 22 Jan 2010

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Biopharmaceuticals; Chugai Pharmaceutical
  • Class Antibacterials; Gastrokinetics; Irritable bowel syndrome therapies; Macrolides
  • Mechanism of Action Motilin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetic gastroparesis; Gastro-oesophageal reflux; Gastroparesis; Irritable bowel syndrome

Most Recent Events

  • 28 Oct 2005 Chugai is preparing to commence phase III studies in the US with GM 611 for the treatment of diabetic gastroparesis
  • 08 Jun 2005 Data presented at the Digestive Disease Week conference (DDW-2005) have been added to the Digestive disorders therapeutic trials section
  • 22 Apr 2005 No development reported - Phase-II for Gastro-oesophageal reflux in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top